
CGON Stock Forecast & Price Target
CGON Analyst Ratings
Bulls say
CG Oncology Inc.’s anticipated launch of its immunotherapy candidate, cretostimogene grenadenorepvec, as a potential bladder-sparing treatment in 2026 project sales growth to approximately $2.6 billion by 2034, indicating a favorable long-term financial outlook. The expected differentiation in efficacy and durability from BOND-003’s data signals a strong potential for regulatory approval, bolstering confidence in the company’s market positioning and its ability to address unmet patient needs in the NMIBC space. Additionally, the capabilities of CG Oncology regarding manufacturing and commercial readiness stand to enhance investor reassurance and firm up its competitive stance against key players like Inlexzo.
Bears say
CG Oncology faces significant risks regarding its commercialization prospects, highlighted by the potential for negative trial outcomes and slower-than-expected trial enrollment, which may hinder market entry and reduce the overall market potential for its therapies. The company's reliance on successful reimbursement from payers could be jeopardized if real-world adherence and durability of treatment outcomes are not demonstrated, especially considering the substantial upfront investment costs associated with its candidate therapies. Furthermore, the possibility of third-party challenges or lapses in intellectual property protection raises additional concerns about CG Oncology's competitive positioning in the biopharmaceutical market.
This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
CGON Analyst Forecast & Price Prediction
Start investing in CGON
Order type
Buy in
Order amount
Est. shares
0 shares